// App-Quantinova.ai

TPS3162 : A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of solid tumors harboring specific HER2-activating mutations (DESTINY-PanTumor01).

Researchers

Presenter

  • Bob T. Li

Principal Investigators

  • Funda Meric-Bernstam

  • Soham D. Puvvada

  • Jacqui Rowbottom

  • Darren Jolliffe

  • Mark Gustavson

  • Ariadna Mendoza-Naranjo

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • AstraZeneca Pharmaceuticals, Gaithersburg, MD

  • AstraZeneca Pharmaceuticals, Cambridge, United Kingdom

  • AstraZeneca Pharmaceuticals, Gaithersburg, MD

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Solid malignancies

  • Lung Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Trastuzumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCT04639219

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved